1-(5-fluoro-1H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinoline | 1027797-71-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-(5-fluoro-1H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinoline
• 英文别名: 1-[(4-fluoro-1H-imidazol-5-yl)methyl]-3,4-dihydro-2H-quinoline
• CAS: 1027797-71-2
• 化学式: C₁₃H₁₄FN₃
• 分子量: 231.273
• InChiKey: VYMGXPFDFQABBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  31.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-[5-fluoro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-4-ylmethyl]-1,2,3,4-tetrahydro-quinoline 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 0.33h， 生成 1-(5-fluoro-1H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinoline
  参考文献：
  名称：

  WO2008/58867

  摘要：

  公开号：

文献信息

• SUBSTITUTED 4-IMIDAZOLES
  申请人：Galley Guido

  公开号：US20080139533A1

  公开（公告）日：2008-06-12

  The present invention relates to a compound of formula I, wherein R 1 is selected from the group consisting of hydrogen and lower alkyl; each R 2 is independently selected from the group consisting of hydrogen and lower alkyl; each R 3 is independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyloxy, benzyloxy, halogen and lower alkyl substituted by halogen; R 4 is selected from the group consisting of hydrogen and lower alkyl; X is selected from the group consisting of —CH 2 —, —CH— and —O—; Y is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CH— and a bond; with the proviso that, when X is —O—, Y is —CH 2 —; Z is selected from the group consisting of —CH 2 — and —CH—; m is 1 or 2; and n is 1 or 2. The invention relates also to a pharmaceutically-acceptable acid-addition salt of such a compound, methods for making the compound, and a composition comprising such a compound. It has been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1.

  本发明涉及一种化合物式I，其中R1选自氢和低碳基的群组；每个R2独立地选自氢和低碳基的群组；每个R3独立地选自氢、低碳基、低烷氧基、苯氧基、苄氧基、卤素和被卤素取代的低碳基的群组；R4选自氢和低碳基的群组；X选自—CH2—、—CH—和—O—的群组；Y选自—CH2—、—CH2CH2—、—CH—和键的群组；但当X为—O—时，Y为—CH2—；Z选自—CH2—和—CH—的群组；m为1或2；n为1或2。本发明还涉及该化合物的药学可接受的酸加成盐、制备该化合物的方法和包含该化合物的组合物。已经发现，式I化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。
• Substituted 4-imidazoles
  申请人：Hoffmann-La Roche Inc.

  公开号：US07858652B2

  公开（公告）日：2010-12-28

  The present invention relates to a compound of formula I, wherein R1 is selected from the group consisting of hydrogen and lower alkyl; each R2 is independently selected from the group consisting of hydrogen and lower alkyl; each R3 is independently selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, phenyloxy, benzyloxy, halogen and lower alkyl substituted by halogen; R4 is selected from the group consisting of hydrogen and lower alkyl; X is selected from the group consisting of —CH2—, —CH— and —O—; Y is selected from the group consisting of —CH2—, —CH2CH2—, —CH— and a bond; with the proviso that, when X is —O—, Y is —CH2—; Z is selected from the group consisting of —CH2— and —CH—; m is 1 or 2; and n is 1 or 2. The invention relates also to a pharmaceutically-acceptable acid-addition salt of such a compound, methods for making the compound, and a composition comprising such a compound. It has been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1.

  本发明涉及一种化合物I，其中R1选自氢和低级烷基组成的群；每个R2独立地选自氢和低级烷基组成的群；每个R3独立地选自氢、低级烷基、低级烷氧基、苯氧基、苄氧基、卤素和被卤素取代的低级烷基组成的群；R4选自氢和低级烷基组成的群；X选自—CH2—、—CH—和—O—组成的群；Y选自—CH2—、—CH2CH2—、—CH—和一个键组成的群；但当X为—O—时，Y为—CH2—；Z选自—CH2—和—CH—组成的群；m为1或2；n为1或2。本发明还涉及这种化合物的药学可接受的酸加成盐、制备该化合物的方法以及包含该化合物的组合物。已经发现，化合物I对追踪胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。
• US7858652B2
  申请人：——

  公开号：US7858652B2

  公开（公告）日：2010-12-28
• [EN] SUBSTITUTED 4-IMIDAZOLES<br/>[FR] 4-IMIDAZOLES SUBSTITUÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2008058867A2

  公开（公告）日：2008-05-22

  [EN] The present invention relates to compounds of formula (I) wherein R¹ is hydrogen or lower alkyl; R² is hydrogen or lower alkyl; R³ is hydrogen, lower alkyl, lower alkoxy, phenyloxy, benzyloxy, halogen or lower alkyl substituted by halogen; R⁴ is hydrogen or lower alkyl; X is -CH₂-, -CH- or -O-; Y is -CH₂-, -CH₂CH₂-, -CH- or a bond; when X is -O-, then Y is -CH₂-; Z is -CH₂- or -CH-; m is 1 or 2; when m is 2, R² may be the same or not; n is 1 or 2; when n is 2, R³ may be the same or not; and to pharmaceutically acceptable acid addition salts. It has been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
  [FR] La présente invention concerne des composés de formule (I) et des sels d'addition d'acide pharmaceutiquement acceptables associés. Dans ladite formule : R¹ représente hydrogène ou un alkyle inférieur; R² représente hydrogène ou un alkyle inférieur; R³ représente hydrogène, un alkyle inférieur, un alcoxy inférieur, phényloxy, benzyloxy, halogène ou un alkyle inférieur substitué par halogène; R⁴ représente hydrogène ou un alkyle inférieur; X représente -CH₂-, -CH- ou -O-; Y représente -CH₂-, -CH₂CH₂-, -CH- ou une liaison, étant entendu que lorsque X représente -O-, Y représente -CH₂-; Z représente -CH₂- ou -CH-; m est égal à 1 ou 2; lorsque m est égal à 2, R² peut être identique ou différent; n est égal à 1 ou 2; lorsque n est égal à 2, R³ peut être identique ou différent. L'on a découvert que les composés de formule (I) présentent une bonne affinité pour les récepteurs associés à une amine de trace (TAARs), en particulier pour TAAR1. Les composés selon l'invention peuvent servir à traiter la dépression, les troubles anxieux, le trouble bipolaire, le trouble déficitaire de l'attention avec hyperactivité (TDAH), les troubles liés au stress, les troubles psychotiques tels que la schizophrénie, les maladies neurologiques telles que la maladie de Parkinson, les troubles neurodégénératifs tels que la maladie d'Alzheimer, l'épilepsie, la migraine, l'hypertension, l'abus de substances psychoactives et les troubles métaboliques tels que les troubles de l'alimentation, le diabète, les complications du diabète, l'obésité, la dyslipidémie, les troubles de la consommation et de l'assimilation d'énergie, les troubles et les dysfonctionnements de l'homéostasie de la température corporelle, les troubles du sommeil et du rythme circadien et les troubles cardio-vasculaires.
• WO2008/58867
  申请人：——

  公开号：——

  公开（公告）日：——